JP2007535293A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007535293A5 JP2007535293A5 JP2006505346A JP2006505346A JP2007535293A5 JP 2007535293 A5 JP2007535293 A5 JP 2007535293A5 JP 2006505346 A JP2006505346 A JP 2006505346A JP 2006505346 A JP2006505346 A JP 2006505346A JP 2007535293 A5 JP2007535293 A5 JP 2007535293A5
- Authority
- JP
- Japan
- Prior art keywords
- glut1
- polypeptide
- seq
- stlv
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 27
- 102000004196 processed proteins & peptides Human genes 0.000 claims 27
- 108090000765 processed proteins & peptides Proteins 0.000 claims 27
- 102000058063 Glucose Transporter Type 1 Human genes 0.000 claims 23
- 108091006296 SLC2A1 Proteins 0.000 claims 23
- 210000004027 cell Anatomy 0.000 claims 15
- 101710091045 Envelope protein Proteins 0.000 claims 8
- 101710188315 Protein X Proteins 0.000 claims 8
- 102100021696 Syncytin-1 Human genes 0.000 claims 8
- 238000001514 detection method Methods 0.000 claims 7
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 6
- 239000012472 biological sample Substances 0.000 claims 6
- 238000000338 in vitro Methods 0.000 claims 6
- 230000002018 overexpression Effects 0.000 claims 6
- 241001466984 Simian T-lymphotropic virus 1 Species 0.000 claims 5
- 241000713309 Simian immunodeficiency virus - agm Species 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 4
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 claims 4
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 230000001575 pathological effect Effects 0.000 claims 4
- 230000007170 pathology Effects 0.000 claims 4
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 241001529934 Simian T-lymphotropic virus 3 Species 0.000 claims 2
- 208000015114 central nervous system disease Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000026278 immune system disease Diseases 0.000 claims 2
- 230000004968 inflammatory condition Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 150000001413 amino acids Chemical group 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 230000037456 inflammatory mechanism Effects 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03291067.1 | 2003-05-02 | ||
| EP03291067 | 2003-05-02 | ||
| PCT/EP2004/004624 WO2004096841A1 (en) | 2003-05-02 | 2004-04-30 | Glut-1 as a receptor for htlv envelopes and its uses |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007535293A JP2007535293A (ja) | 2007-12-06 |
| JP2007535293A5 true JP2007535293A5 (cg-RX-API-DMAC7.html) | 2012-01-26 |
| JP5612239B2 JP5612239B2 (ja) | 2014-10-22 |
Family
ID=33396025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006505346A Expired - Lifetime JP5612239B2 (ja) | 2003-05-02 | 2004-04-30 | Ｈｔｌｖエンベロープのレセプターとしてのｇｌｕｔ１及びその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US7642061B2 (cg-RX-API-DMAC7.html) |
| EP (3) | EP3168227B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5612239B2 (cg-RX-API-DMAC7.html) |
| DK (1) | DK1648926T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2740827T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2004096841A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1648926T3 (da) * | 2003-05-02 | 2013-10-14 | Centre Nat Rech Scient | Glut-1 som en receptor til htlv-kapper og anvendelser heraf |
| US9777044B2 (en) * | 2003-05-02 | 2017-10-03 | Centre National De La Recherche Scientifique (Cnrs) | GLUT-1 as a receptor for HTLV envelopes and its uses |
| US20070231260A1 (en) * | 2005-09-30 | 2007-10-04 | Xenoport, Inc. | Transporter-targeted methods of diagnosis and treatment |
| CN102326079B (zh) * | 2009-01-09 | 2015-04-15 | 国家科研中心 | 新型受体结合配体及其在检测具有生物学益处的细胞中的用途 |
| US8870950B2 (en) | 2009-12-08 | 2014-10-28 | Mitral Tech Ltd. | Rotation-based anchoring of an implant |
| US20130260394A1 (en) | 2010-09-17 | 2013-10-03 | Centre National De La Recherche Scientifique | Method for the diagnosis and/or prognosis of inflammatory states |
| UA128249C2 (uk) * | 2015-03-10 | 2024-05-22 | Зе Трастіс Оф Коламбія Юніверсіті Ін Зе Сіті Оф Нью-Йорк | Рекомбінантна конструкція glut1 аденоасоційованого вірусного вектора і спосіб відновлення експресії glut1 на її основі |
| EP3861350A1 (en) | 2018-10-05 | 2021-08-11 | Metafora Biosystems | Use of ligands derived from receptor-binding domain of porcine endogenous retrovirus type b for diagnosing smvt-related diseases |
| CN113527429B (zh) * | 2020-04-15 | 2024-04-16 | 辽宁中健医药科技有限公司 | 人肝癌细胞特异结合多肽及其用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5614366A (en) * | 1986-12-31 | 1997-03-25 | Genelabs Technologies, Inc. | HTLV-I peptide antigens and kit |
| WO1988005783A1 (en) | 1987-01-28 | 1988-08-11 | Ortho Pharmaceutical Corporation | Immunosuppressive peptides and methods of use |
| JPH10512151A (ja) | 1995-01-13 | 1998-11-24 | ヴァイロジェネティクス コーポレイション | Ｈｔｌｖ抗原を発現する組換え弱毒化ポックスウイルスを含有する免疫原性組成物 |
| US5897991A (en) * | 1995-06-07 | 1999-04-27 | The Mount Sinai Medical Center | Highly sensitive immunocytochemical method for diagnosis of malignant effusions |
| US5698410A (en) * | 1995-06-07 | 1997-12-16 | Mount Sinai School Of Medicine Of The City University Of New York | Highly sensitive immunocytochemical method for diagnosis of malignant effusions |
| WO1997015668A2 (en) | 1995-10-23 | 1997-05-01 | Board Of Regents, The University Of Texas System | Methods and compositions comprising glut-2 and glut-2 chimeras |
| JP2002513381A (ja) * | 1996-07-22 | 2002-05-08 | ザ ロックフェラー ユニバーシティー | ＨＴＬＶ―Ｉ感染およびＨＴＬＶ―ＩＩ感染を予防するためのｅｎｖ―糖タンパク質ワクチン |
| AU756515B2 (en) | 1998-03-13 | 2003-01-16 | Johns Hopkins University School Of Medicine, The | The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy or ocular inflammation |
| AU3991499A (en) | 1998-05-15 | 1999-12-06 | Joslin Diabetes Center | Independent regulation of basal and insulin-stimulated glucose transport |
| DK1648926T3 (da) * | 2003-05-02 | 2013-10-14 | Centre Nat Rech Scient | Glut-1 som en receptor til htlv-kapper og anvendelser heraf |
-
2004
- 2004-04-30 DK DK04730535.4T patent/DK1648926T3/da active
- 2004-04-30 JP JP2006505346A patent/JP5612239B2/ja not_active Expired - Lifetime
- 2004-04-30 EP EP16197090.0A patent/EP3168227B1/en not_active Expired - Lifetime
- 2004-04-30 EP EP12194035.7A patent/EP2610265B1/en not_active Expired - Lifetime
- 2004-04-30 WO PCT/EP2004/004624 patent/WO2004096841A1/en not_active Ceased
- 2004-04-30 EP EP04730535.4A patent/EP1648926B1/en not_active Expired - Lifetime
- 2004-04-30 US US10/555,289 patent/US7642061B2/en active Active
- 2004-04-30 ES ES16197090T patent/ES2740827T3/es not_active Expired - Lifetime
-
2009
- 2009-08-26 US US12/547,924 patent/US8945583B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11793855B2 (en) | TFPI inhibitors and methods of use | |
| JP2014502149A5 (cg-RX-API-DMAC7.html) | ||
| US20210347824A1 (en) | Antigenic peptides and uses thereof for diagnosing and treating autism | |
| JP2007535293A5 (cg-RX-API-DMAC7.html) | ||
| CN106456700B (zh) | 糖尿病治疗和预防的新靶标 | |
| US7070940B2 (en) | Method for determining the ability of a compound to modify the interaction between parkin and the p38 protein | |
| CN104177476B (zh) | 一种靶向人癌细胞的多肽及其应用 | |
| KR101297667B1 (ko) | ｂｃｌ―２ 단백질 표적 펩타이드 및 이의 이용 | |
| JP2023502198A (ja) | 診断及び処置のための抗原ニューロン特異的エノラーゼペプチド | |
| WO2014014819A2 (en) | Methods of treating glucose metabolism disorders | |
| US20240309060A1 (en) | Polypeptide bax/npm inhibitors | |
| WO2007055341A1 (ja) | 示差的な糖尿病の予知・診断方法および糖尿病予知・診断用キット | |
| US20070298022A1 (en) | Identification of Phospholipase A2 as Target in Cancer Treatment, with Special Emphasis on Colorectal Cancer and Its Mechanism of Action | |
| CN100436595C (zh) | 人cyld基因及其编码产物在制备诊断试剂中的用途 | |
| CN119730873A (zh) | 肿瘤相关抗原的微生物类似物及其用途 | |
| KR20120132455A (ko) | ｂｃｌ?２ 단백질 표적 펩타이드 및 이의 이용 | |
| WO2009096088A1 (ja) | 関節炎誘発原性ペプチド | |
| WO2014014816A2 (en) | Methods of treating glucose metabolism disorders |